Education
About Us
Working with TipRanks
Follow Us
Symbio Pharmaceuticals Limited (JP:4582)
:4582
RESEARCH TOOLSreports
Total Valuation
Symbio Pharmaceuticals Limited has a market cap or net worth of ¥7.79B. The enterprise value is ―.
Market Cap¥7.79B
Enterprise Value―
Share Statistics
Symbio Pharmaceuticals Limited has 48,798,880 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48,798,880
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Symbio Pharmaceuticals Limited’s return on equity (ROE) is -0.91 and return on invested capital (ROIC) is -92.90%.
Return on Equity (ROE)-0.91
Return on Assets (ROA)-0.77
Return on Invested Capital (ROIC)-92.90%
Return on Capital Employed (ROCE)-0.92
Revenue Per Employee22.71M
Profits Per Employee-35.50M
Employee Count108
Asset Turnover0.49
Inventory Turnover2.43
Valuation Ratios
The current PE Ratio of Symbio Pharmaceuticals Limited is -2.34. Symbio Pharmaceuticals Limited’s PEG ratio is -0.26.
PE Ratio-2.34
PS Ratio0.00
PB Ratio1.88
Price to Fair Value2.14
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio-0.26
Income Statement
In the last 12 months, Symbio Pharmaceuticals Limited had revenue of 2.45B and earned -3.83B in profits. Earnings per share was -85.00.
Revenue2.45B
Gross Profit1.87B
Operating Income-3.88B
Pretax Income-3.81B
Net Income-3.83B
EBITDA-3.78B
Earnings Per Share (EPS)-85.00
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Symbio Pharmaceuticals Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.68
52-Week Price Change-3.03%
50-Day Moving Average160.88
200-Day Moving Average214.42
Relative Strength Index (RSI)54.31
Average Volume (3m)355.62K
Important Dates
Symbio Pharmaceuticals Limited upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
Symbio Pharmaceuticals Limited as a current ratio of 6.43, with Debt / Equity ratio of 0.00%
Current Ratio6.43
Quick Ratio6.12
Debt to Market Cap0.00
Net Debt to EBITDA1.05
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Symbio Pharmaceuticals Limited has paid 26.52M in taxes.
Income Tax26.52M
Effective Tax Rate>-0.01
Enterprise Valuation
Symbio Pharmaceuticals Limited EV to EBITDA ratio is -1.33, with an EV/FCF ratio of -1.46.
EV to Sales2.04
EV to EBITDA-1.33
EV to Free Cash Flow-1.46
EV to Operating Cash Flow-1.47
Balance Sheet
Symbio Pharmaceuticals Limited has ¥3.96B in cash and marketable securities with ¥0.00 in debt, giving a net cash position of -¥3.96B billion.
Cash & Marketable Securities¥3.96B
Total Debt¥0.00
Net Cash-¥3.96B
Net Cash Per Share-¥81.22
Tangible Book Value Per Share¥93.08
Margins
Gross margin is 76.37%, with operating margin of -158.06%, and net profit margin of -156.28%.
Gross Margin76.37%
Operating Margin-158.06%
Pretax Margin-155.20%
Net Profit Margin-156.28%
EBITDA Margin-154.14%
EBIT Margin-158.06%
Analyst Forecast
The average price target for Symbio Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-56.12%
EPS Growth Forecast-73.82%